At the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer Oncology will present the following data:

**Axitinib:**

(Abstract #4546) Poster Discussion Session: Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients. M. Dror Michaelson. Saturday, June 2. Session Time: 8:00am - 12:00pm CDT, Session Location: E450a. Discussion Time: 12:00pm – 1:00pm CDT, Discussion Location: E Arie Crown Theater. *(Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)*


(Abstract #4503) Oral Abstract Session: Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. Brian I. Rini. Saturday, June 2. Session Time: 3:00pm – 6:00pm CDT. Presentation Time: 4:00pm – 4:15pm CDT. Location: E Arie Crown Theater. *(Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)*

**Bosutinib:**

(Abstract #6512) Poster Discussion Session: BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. Carlo Gambacorti-Passerini. Friday, June 1. Session Time: 1:00pm – 5:00pm CDT, Session Location: S405. Discussion Time: 4:30pm – 5:30pm CDT, Discussion Location: S406. *(Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)*

(Abstract #6511) Poster Discussion Session: Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome-positive (Ph+) leukemia in older versus younger patients (pts). Tim H. Brümmendorf. Friday, June 1. Poster Session Time: 1:00pm – 5:00pm CDT, Session Location: S405. Discussion Time: 4:30pm – 5:30pm CDT, Discussion Location: S406. *(Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)*

**Crizotinib:**

(Abstract #7508) Clinical Science Symposium: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Alice T. Shaw. Saturday, June 2. Session Time: 8:00am – 9:30am CDT. Discussion Time: 8:00am – 8:15am CDT. Session Location: E Hall D2. *(Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)*

See Below for Embargo Dates


(Abstract #7599) Poster Session: A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). Giorgio Scagliotti. Saturday, June 2. Session Time: 1:15pm – 5:15pm CDT. Session Location: S Hall A2. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Abstract #7600) Poster Session: Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. Gregory A. Otterson. Saturday, June 2. Session Time: 1:15pm – 5:15pm CDT. Location: S Hall A2. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Abstract #2610) Poster Session: Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Sai-Hong I. Ou. Monday, June 4. Session Time: 8:00am – 12:00pm CDT. Session Location: S Hall A2. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Dacomitinib (PF-00299804):

(Abstract #TPS7615) Trials in Progress Poster Session: ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC) - A randomized double-blind phase III study. Michael J. Boyer. Saturday, June 2. Session Time: 1:15pm – 5:15pm CDT. Session Location: S Hall A2. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Abstract #7530) Poster Discussion Session: First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. Mark G Kris. Tuesday, June 5. Poster Session Time: 8:00am - 12:00pm CDT, Session Location: E450a. Discussion Time: 11:30am - 12:30pm CDT, Discussion Location: E354a. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

Sunitinib:

(Abstract #4542) Poster Discussion Session: Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials. Ana M. Molina. Saturday, June 2. Session Time: 8:00am - 12:00pm CDT, Session Location: E450a. Discussion Time: 12:00pm - 1:00pm CDT, Discussion Location: E Arie Crown Theater. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Abstract #4118) Poster Session: Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). Aaron Vinik. Monday, June 4. Session Time: 8:00am - 12:00pm CDT. Location: S Hall A2. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)
(Abstract #6092) Poster Session: Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC). David Cella. Monday, June 4. Session Time: 1:15pm - 5:15pm CDT. Session Location: S Hall A2. (Emargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

Early Development Compounds:

(Abstract #3032) Poster Discussion Session: Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib. Lee S. Rosen. Saturday, June 2. Poster Session Time: 1:15pm - 5:45pm CDT, Session Location: S405. Discussion Time: 4:45pm – 5:45pm CDT, Discussion Location: S406. (Embargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

(Abstract #2595) Poster Session: Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors. Erjian Wang. Monday, June 4. Session Time: 8:00am - 12:00pm CDT. Session Location: S Hall A2. (Emargoed until Wednesday, May 16, 2012 at 6:00pm EDT)

###